Chidamide for Refractory/Relapsed Peripheral T Cell Lymphoma

Summary

This trial intends: 1.To evaluate the concentration of Chidamide in the serum and cerebral-spinal fluid of PTCL patients at certain time points after taking the medicine, to evaluate the pharmacokinetics of Chidamide in these patients and its CNS (central nervous system) distribution. 2\. To evaluate the efficiency and safety of Chidamide in PTCL patients.

Timeline

Start

2016-03

Primary completion

2019-01

Completion

2019-01

Drugs

Indications